In this article, we will look at the 11 Best High Volume Penny Stocks to Buy Now.

After a prolonged period where mega-cap stocks dominated returns, smaller and more speculative names are starting to see renewed trading activity. Increased volume often reflects growing investor attention, and historically, these shifts have coincided with periods where risk appetite begins to expand across the market.

Institutional investors have started to highlight a more constructive backdrop for smaller-cap equities. Franklin Templeton’s report entitled “What’s next for US small-caps in 2026?” notes that “both small-cap quality and value are poised for meaningful rebounds in 2026,” adding that “2026 could be the year that small-caps reassert themselves.” The firm also points out that the earnings growth of small-caps is expected to beat that of large-caps in 2026. Janus Henderson echoes this view, stating that “multiple drivers beyond interest rates support small caps heading into 2026,” while noting that “small-cap valuations remain historically cheap relative to large caps.” Institutional investors are beginning to see a scenario where underfollowed and lower-priced stocks could attract more attention as capital rotates across the market.

These perspectives point to a market environment where smaller, more actively traded stocks may begin to gain relevance, especially as investors look beyond the largest names for new opportunities. With that in mind, we take a closer look at the 11 Best High Volume Penny Stocks to Buy Now.

Our Methodology

We used screeners to identify stocks that are trading below $5 per share and have an average volume of at least 5 million. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

11. Sabre Corporation (NASDAQ:SABR)

On March 13, 2026, BofA analyst Victor Cheng lowered the price target on Sabre Corporation (NASDAQ:SABR) to $2.40 from $2.90 previously and maintained a Buy rating. BofA said that Sabre Corporation (NASDAQ:SABR) is still expected to outpace Global Distribution System industry growth in air bookings, forecasting 4.3% growth in FY26 versus about 1.4% for the industry, but cited lower growth and free cash flow in the outer years for the reduced target.

On March 5, 2026, Sabre Corporation (NASDAQ:SABR) and Constellation Software, which owns approximately 12.7% of Sabre’s outstanding shares, entered into a strategic governance agreement. As part of the agreement, Sabre will appoint Damian McKay, CEO of Vela Software Group, to its Board of Directors, and the company will terminate its shareholder rights plan announced on March 1. McKay joined Vela in 2015 through the acquisition of Datamine, where McKay had served as CEO, and has held various leadership roles across energy and software businesses prior to the current position.

Last month, Sabre reported Q4 adjusted EPS of (1c) versus the (5c) consensus estimate. Revenue totaled $667M compared with the $654.08M consensus estimate. CEO Kurt Ekert said the company ended the year with “strong momentum” and is positioned for accelerating performance, noting that Sabre generated full-year positive Pro Forma Free Cash Flow and continued advancing its AI capabilities for the travel industry despite a challenging 2025.

Sabre Corporation (NASDAQ:SABR) provides software and technology solutions for the global travel industry, including its Sabre Mosaic marketplace connecting travel suppliers and buyers.

10. Humacyte, Inc. (NASDAQ:HUMA)

On March 17, 2026, Humacyte, Inc. (NASDAQ:HUMA) submitted a Marketing Authorization Application to the Israel Ministry of Health for approval of its acellular tissue-engineered vessel, Symvess, for arterial trauma repair. The company is also pursuing a pathway to make Symvess available in Israel on a hospital-by-hospital basis ahead of potential approval. Symvess is currently approved by the FDA for extremity vascular trauma, while other uses remain investigational and not yet approved by regulatory agencies.

Last month, Humacyte, Inc. (NASDAQ:HUMA) presented long-term data on Symvess at the Vascular & Endovascular Surgery Society Annual Winter Meeting 2026. In the V005 trial, the product maintained structural integrity and showed low infection rates with high levels of limb salvage over follow-up periods of up to 36 months. Among 54 patients treated in the Phase 2/3 study where standard vein grafts were not feasible, outcomes stabilized after early complications, with infection-free rates reaching 92.9% from months 3 to 36 and no infections reported after day 37. Limb salvage rates were 87.3% at 12 months and 82.5% at 24 months.

Humacyte, Inc. (NASDAQ:HUMA) develops and manufactures bioengineered human tissues designed for implantation across multiple therapeutic areas.